ROCKVILLE, Md., Aug. 1, 2023 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced that it will host one-on-one investor meetings at the 2023 Wedbush PacGrow Healthcare Conference on Tuesday, June 8, 2023.
2023 Wedbush PacGrow Healthcare Conference
Date: Tuesday, August 8, 2023
About REGENXBIO Inc.
REGENXBIO is a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy. REGENXBIO's NAV Technology Platform, a proprietary adeno-associated virus (AAV) gene delivery platform, consists of exclusive rights to more than 100 novel AAV vectors, including AAV7, AAV8 and AAV9. REGENXBIO and its third-party NAV Technology Platform Licensees are applying the NAV Technology Platform in the development of a broad pipeline of candidates, including late-stage and commercial programs, in multiple therapeutic areas. REGENXBIO is committed to a "5x'25" strategy to progress five AAV Therapeutics from its internal pipeline and licensed programs into pivotal-stage or commercial products by 2025.
Contact:
Investors:
Chris Brinzey
ICR Westwicke
339-970-2843
This email address is being protected from spambots. You need JavaScript enabled to view it.
| Last Trade: | US$5.94 |
| Daily Change: | -0.22 -3.57 |
| Daily Volume: | 624,507 |
| Market Cap: | US$294.330M |
March 19, 2025 March 13, 2025 March 10, 2025 March 04, 2025 January 30, 2025 | |
Terns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...
CLICK TO LEARN MORE
C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...
CLICK TO LEARN MORE
